沃森生物(300142.SZ)快速拉昇漲超8%首度站上70元 市值突破千億
格隆匯7月23日丨沃森生物(300142.SZ)快速拉昇,目前漲幅擴大至近9%,最高價報70元,為首度站上70元關口,再創歷史新高,最新總市值1073億元。該股年內累漲115%。工信部今日表示,我國現有13家企業陸續開展了新冠疫苗產能建設,其中9家企業已經獲批開展臨牀試驗。工信部密切跟蹤新冠疫苗研發過程,指導企業加快疫苗產業化進度,全面做好規模化生產準備。一是加強疫苗的生產調度。二是推動加快疫苗產能建設。三是組織開展產業鏈供需對接。據醫藥行業分析師稱,復星醫藥和沃森生物兩家公司都具備研發生產疫苗的能力。復星醫藥A股已漲停,H股漲近9%。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.